New Developments in the Prophylactic Drug Treatment of Pediatric Migraine: What Is New in 2017 and Where Does It Leave Us?
- 980 Downloads
Purpose of Review
Headaches in children are quite common; however, the study and characterization of headache disorders in the pediatric age group has historically been limited. Because of the lack of controlled studies on prophylactic treatment of headache disorders in this age group, the diagnosis of migraine rests on criteria similar those in adults. Likewise, data from adult studies is often inferred and applied to children. Although it appears that many preventives are safe in children, currently none are FDA or EMA approved for this age group. Consequently, many children who present to their primary care physicians with migraines do not receive any preventive therapy despite experiencing significant disability.
Controlled clinical trials investigating the use of preventive medications in children have suffered from high placebo response rates. The shorter duration of headaches and other characteristic features seen in children are such that designing randomized controlled trials in this age group is more problematic and limiting. Treatment practices vary widely, even among specialists, due to the absence of evidence-based guidelines from clinical trials. The Childhood and Adolescent Migraine Prevention Study (CHAMP) was developed to examine the effectiveness of two of the most widely prescribed preventive medications for pediatric migraine and help narrow this gap. To date, it has been the largest enrolling study of its kind within the pediatric migraine world; its results and implications will be discussed and considered here.
The CHAMP trial was discontinued early on account of futility and exhibited that neither of two preventive medications for pediatric migraine was more effective than placebo in reducing the number of headache days over a period of 24 weeks. Subjects in the amitriptyline and topiramate groups had higher rates of adverse events than those who had received placebo.
KeywordsMigraine Pediatric migraine Preventive headache treatment Prophylactic headache treatment Nonpharmacologic treatment CHAMP: Childhood and adolescent migraine prevention study
Compliance with Ethical Standards
Conflict of Interest
Joanne Kacperski and Allyson Bazarsky declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.• Hershey AD, Powers SW, Coffey CS, Eklund DD, Chamberlin LA, Korbee LL, et al. Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine. Headache. 2013;53(5):799–816. doi: 10.1111/head.12105. The authors discuss the goals of CHAMP study in detail including its study design aimed to obtain level 1 evidence for the effectiveness of amitriptyline and topiramate in the prevention of migraine in children and adolescents and to provide information to the practicing physician as how to best prevent migraine in children and adolescents and subsequently improve the disability and outcomes. The study population is described in detail. CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff’s headache and other headache pain. 7th ed. Oxford: Oxford University Press; 2001.Google Scholar
- 17.•• Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376(2):115–24. doi: 10.1056/NEJMoa1610384. One of the largest NIH-funded pediatric studies in the US, the CHAMP study demonstrated that there were no significant differences in reduction in headache frequency or headache-related disability in childhood and adolescent migraine with amitriptyline, topiramate, or placebo over a period of 24 weeks. In addition, the active drugs were associated with higher rates of adverse events. CrossRefPubMedGoogle Scholar
- 18.• Powers SW, Hershey AD, Coffey CS, Chamberlin LA, Ecklund D, Sullivan SM, et al. The Childhood and Adolescent Migraine Prevention (CHAMP) study: a report on baseline characteristics of participants. Headache. 2016;56:859–70. doi: 10.1111/head.12810. Outlines the characteristics of the participants in CHAMP and highlights the importance of recruiting a population representive of those children suffering with chronic and episodic migraines.
- 19.Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004;63:2215–24. doi: 10.1212/01.WNL.0000147332.41993.90.CrossRefPubMedGoogle Scholar
- 28.Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd ed. Cephalalgia. 2004;24(Suppl 1):9–160.Google Scholar
- 34.• Powers SW, Hershey AD, Coffey CS. The Childhood and Adolescent Migraine Prevention (CHAMP) study: “What do we do now?”. Headache. 2017;57(2):180–3. doi: 10.1111/head.13025. Briefly and succinctly discussed the implications of the CHAMP study and discusses directions for future research. CrossRefPubMedGoogle Scholar